New Prostate Cancer Drug Shows Promise in Early Trial
Patients with advanced prostate cancer saw significant tumor reduction in a recent Phase 1/2 study of a new oral drug.
Updated on Oct. 24, 2026 in Cancer
Johnson & Johnson has reported positive early trial results for the experimental prostate cancer drug JNJ-6143. The oral medication showed significant tumor reduction in patients with metastatic castration-resistant prostate cancer who had previously received multiple therapies.
Why it matters
For patients with advanced prostate cancer who have exhausted other options, these preliminary findings suggest a potential new way to target cancer cells. Ongoing testing is necessary to confirm the drug's safety and effectiveness in a larger patient group.
In a Phase 1/2 trial of 31 evaluable patients with metastatic castration-resistant prostate cancer, 77% achieved a 50% or greater reduction in prostate-specific antigen (PSA) levels. While these early-stage results are promising, the drug's long-term efficacy remains under investigation.
The players
Johnson & Johnson
A global pharmaceutical company focused on developing therapies for oncology and other medical conditions.
The details
The drug candidate, JNJ-6143, is an oral treatment that works by binding to both androgen receptors and the BRD4 protein to induce programmed cell death in cancer cells. The Phase 2 trial protocol utilizes 28-day treatment cycles at a 50 mg dose. During the initial trial, fewer than 60% of patients reported treatment-related adverse events, and 10% experienced serious treatment-related adverse events.
Timeline
Johnson & Johnson acquired the RIPTAC platform developer Halda in 2025.
Phase 1/2 trial results for JNJ-6143 were presented in October 2026.
Health Landscape
This drug candidate represents a clinical application of the RIPTAC platform designed to improve the precision of targeting cancer cells. It reflects a broader shift toward developing therapies that specifically disrupt protein function in treatment-resistant cancers.
Patients managing metastatic castration-resistant prostate cancer should monitor for upcoming data as the trial scales to 100 participants. It is worth discussing with your oncologist whether enrollment in advanced clinical trials might be appropriate for your specific care plan.
The takeaway
These early results offer a potential new path for those with advanced prostate cancer who have undergone multiple previous therapies. Patients and their caregivers should consult with a specialist about emerging clinical trial opportunities for new, targeted treatment options.
What happens next
Johnson & Johnson is currently initiating a Phase 2 trial with plans to enroll approximately 100 patients to further evaluate the drug.
Further reading
For more information on current treatment landscapes, explore the latest research in our Cancer section.
